Ser678

Site Information
KVPQRTtsIsPALAR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3215502

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 7 , 8 , 9 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 )
Disease tissue studied:	breast cancer ( 3 , 8 ) , leukemia ( 11 , 22 ) , acute myelogenous leukemia ( 11 ) , chronic myelogenous leukemia ( 22 ) , lung cancer ( 8 ) , non-small cell lung cancer ( 8 ) , pancreatic ductal adenocarcinoma ( 4 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 4 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 14 ) , 293 (epithelial) [AT1 (human), transfection] ( 13 ) , 293 (epithelial) ( 19 ) , 786-O (renal) [VHL (human), transfection] ( 1 ) , 786-O (renal) ( 1 ) , BT-20 (breast cell) ( 8 ) , BT-549 (breast cell) ( 8 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 9 ) , Flp-In T-Rex-293 (epithelial) ( 9 ) , GM00130 (B lymphocyte) ( 15 ) , H2009 (pulmonary) ( 8 ) , H2077 (pulmonary) ( 8 ) , H2887 (pulmonary) ( 8 ) , H322M (pulmonary) ( 8 ) , HCC1359 (pulmonary) ( 8 ) , HCC1937 (breast cell) ( 8 ) , HCC2279 (pulmonary) ( 8 ) , HCC366 (pulmonary) ( 8 ) , HCC4006 (pulmonary) ( 8 ) , HCC78 (pulmonary) ( 8 ) , HCC827 (pulmonary) ( 8 ) , HeLa (cervical) ( 21 ) , HeLa S3 (cervical) ( 20 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 3 ) , HMLER ('stem, breast cancer') ( 3 ) , HOP62 (pulmonary) ( 8 ) , HUES-7 ('stem, embryonic') ( 17 ) , HUES-9 ('stem, embryonic') ( 12 ) , Jurkat (T lymphocyte) ( 23 ) , K562 (erythroid) ( 7 , 16 , 22 ) , KG-1 (myeloid) ( 11 ) , LOU-NH91 (squamous) ( 8 ) , MCF-7 (breast cell) ( 8 ) , MDA-MB-231 (breast cell) ( 8 ) , MDA-MB-435S (breast cell) ( 18 ) , MDA-MB-468 (breast cell) ( 8 ) , MV4-11 (macrophage) ( 18 ) , NCI-H1395 (pulmonary) ( 8 ) , NCI-H1568 (pulmonary) ( 8 ) , NCI-H2030 (pulmonary) ( 8 ) , NCI-H2172 (pulmonary) ( 8 ) , NCI-H322 (pulmonary) ( 8 ) , NCI-H460 (pulmonary) ( 8 ) , NCI-H520 (squamous) ( 8 ) , NCI-H647 (pulmonary) ( 8 ) , PC9 (pulmonary) ( 8 ) , WM239A (melanocyte) ( 2 )

References
1	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
4	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
5	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
6	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
7	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
8	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
9	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
10	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
11	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
12	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
13	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
14	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
15	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
16	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
17	Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26 19664995 Curated Info
18	Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64 19369195 Curated Info
19	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
20	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info
21	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
22	Stokes M (2008) CST Curation Set: 4388; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
23	Stokes M (2008) CST Curation Set: 3881; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info